{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:42:43Z","timestamp":1787010163437,"version":"build-2736575974"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"45","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,7]]},"abstract":"<jats:p>\n                    Ovarian cancer is typically diagnosed at stages 3 or 4, and up to 80% of patients develop peritoneal metastasis. Although initial chemotherapy with carboplatin and paclitaxel is effective, recurrence rates for recurrent ovarian cancer (ROC) reach approximately 75%. Recently, a minimally invasive approach known as pressurized intraperitoneal aerosol chemotherapy (PIPAC) has been developed, in which chemotherapy is administered as a pressurized aerosol under laparoscopy. This study aimed to present the early outcomes of PIPAC for peritoneal carcinomatosis due to ROC. Data from ROC patients with ROC treated between January 2020 and January 2025 were retrospectively reviewed. PIPAC was performed alongside systemic chemotherapy for 6-week cycles, with at least 3 sessions. The chemotherapy regimen consisted of doxorubicin 2.1\u2009mg\/m\u00b2 and cisplatin 10.5\u2009mg\/m\u00b2 administered via a nebulizer and injector, respectively, at 37\u00b0C for 30 minutes. Statistical analysis was conducted using SPSS version 25.0. Normality was assessed with histogram plots and the Shapiro\u2013Wilk test, as it is more appropriate for small sample sizes. Categorical variables were compared with the chi-squared test. The Mann\u2013Whitney\n                    <jats:italic toggle=\"yes\">U<\/jats:italic>\n                    and Kruskal\u2013Wallis tests were used for non-parametric comparisons, with post hoc analysis as needed. Spearman correlation assessed relationships between variables. Cox regression analyzed factors affecting survival, and Kaplan\u2013Meier analysis was used for overall survival. A\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    -value\u2005&lt;\u2005.05 was considered statistically significant. A total of 26 PIPAC cycles were performed in 11 ROC patients with ROC. The mean pretreatment Peritoneal Carcinomatosis Index score was 23.18, which decreased to 15.36 after systemic chemotherapy and PIPAC. According to the Peritoneal Regression Grading Score, 3 (27.3%) patients had a complete response, 4 (36.4%) had a major response, 3 (27.3%) had a minor response, and 1 (9%) had no response. Two patients (18.2%) underwent secondary cytoreductive surgery\u2005+\u2005hyperthermic intraperitoneal chemotherapy. The median overall survival was 15.13 months. Early results indicated that PIPAC may improve survival in patients with platinum-resistant ROC without increasing morbidity. Approximately 20% of patients are candidates for secondary cytoreductive surgery. The low toxicity and repeatability of PIPAC when combined with systemic chemotherapy may improve treatment efficacy. Larger multicenter randomized trials are needed.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000045927","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T18:01:42Z","timestamp":1762538502000},"page":"e45927","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Pressurized intraperitoneal aerosol chemotherapy in peritoneal carcinomatosis due to recurrent ovarian cancer"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5929-8639","authenticated-orcid":false,"given":"Pirilti","family":"\u00d6zcan","sequence":"first","affiliation":[{"name":"Department of General Surgery, Yerk\u00f6y \u015eehit Korgeneral Osman Erba\u015f State Hospital, Yerk\u00f6y, Yozgat, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7214-2276","authenticated-orcid":false,"given":"\u00d6zg\u00fcl","family":"D\u00fczg\u00fcn","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, University of Health Sciences, \u0130stanbul Umraniye Training and Research Hospital, Istanbul, T\u00fcrkiye."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20260729","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s10354-014-0312-y","article-title":"Pressurized intraperitoneal chemotherapy (PIPAC) in women with gynecologic malignancies: a review.","volume":"164","author":"Tempfer","year":"2014","journal-title":"Wien Med Wochenschr"},{"key":"R3-20260729","doi-asserted-by":"crossref","first-page":"16061","DOI":"10.1038\/nrdp.2016.61","article-title":"Ovarian cancer.","volume":"2","author":"Matulonis","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"R4-20260729","first-page":"CD007565","article-title":"Optimal primary surgical treatment for advanced epithelial ovarian cancer.","volume":"10","author":"Elattar","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"R5-20260729","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1310\/hpj4905-425","article-title":"Paclitaxel and carboplatin (TC) regimen for ovarian cancer.","volume":"49","author":"Akin","year":"2014","journal-title":"Hosp Pharm"},{"key":"R6-20260729","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol"},{"key":"R7-20260729","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.3802\/jgo.2023.34.e44","article-title":"Effectiveness and safety of nab-paclitaxel and platin um as first-line chemotherapy for ovarian cancer: a retrospective study.","volume":"34","author":"Wang","year":"2023","journal-title":"J Gynecol Oncol"},{"key":"R8-20260729","doi-asserted-by":"crossref","first-page":"25","DOI":"10.52054\/FVVO.15.1.060","article-title":"Laparoscopic selection for surgery in epithelial ovarian cancer. A short review.","volume":"15","author":"Ghirardi","year":"2023","journal-title":"Facts Views Vis Obgyn"},{"key":"R9-20260729","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1200\/JCO.2017.35.15_suppl.5501","article-title":"Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III\/ENGOT ov20.","volume":"35","author":"Du Bois","year":"2017","journal-title":"J Clin Oncol"},{"key":"R10-20260729","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer.","volume":"378","author":"van Driel","year":"2018","journal-title":"N Engl J Med"},{"key":"R11-20260729","doi-asserted-by":"crossref","first-page":"100586","DOI":"10.1016\/j.esmoop.2022.100586","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials.","volume":"7","author":"Filis","year":"2022","journal-title":"ESMO Open"},{"key":"R12-20260729","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.21873\/anticanres.15970","article-title":"Hyperthermic intraperitoneal chemotherapy in the management of primary epithelial ovarian cancer: a debated issue for gynecologic oncologists.","volume":"42","author":"Gadducci","year":"2022","journal-title":"Anticancer Res"},{"key":"R13-20260729","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1245\/s10434-013-3213-1","article-title":"Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy.","volume":"21","author":"Solass","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"R14-20260729","first-page":"e27837","article-title":"Is pressurized intraperitoneal aerosolized chemotherapy (PIPAC) effective in ovarian cancer with peritoneal metastasis?","volume":"14","author":"Mohammad","year":"2022","journal-title":"Cureus"},{"key":"R15-20260729","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00404-018-4784-7","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal carcinomatosis: systematic review of clinical and experimental evidence with special emphasis on ovarian cancer.","volume":"298","author":"Tempfer","year":"2018","journal-title":"Arch Gynecol Obstet"},{"key":"R16-20260729","doi-asserted-by":"crossref","first-page":"1204886","DOI":"10.3389\/fonc.2023.1204886","article-title":"Descriptive review of current practices and prognostic factors in patients with ovarian cancer treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC): a multicentric, retrospective, cohort of 234 patients.","volume":"13","author":"Kefleyesus","year":"2023","journal-title":"Front Oncol"},{"key":"R17-20260729","doi-asserted-by":"crossref","first-page":"20180114","DOI":"10.1515\/pp-2018-0114","article-title":"PIPAC-OV3: a multicenter, open-label, randomized, two-arm phase III trial of the effect on progression-free survival of cisplatin and doxorubicin as pressurized intra-peritoneal aerosol chemotherapy (PIPAC) vs. chemotherapy alone in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.","volume":"3","author":"Bakrin","year":"2018","journal-title":"Pleura Peritoneum"},{"key":"R18-20260729","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1515\/pp-2023-0049","article-title":"Outcome of patients with peritoneal metastasis from ovarian cancer treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC).","volume":"9","author":"Foslund","year":"2024","journal-title":"Pleura Peritoneum"},{"key":"R19-20260729","doi-asserted-by":"crossref","first-page":"1404936","DOI":"10.3389\/fonc.2024.1404936","article-title":"Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) experience in patients with recurrent low grade serous ovarian carcinoma (LGSOC): sub-cohort report of phase 1 clinical trial.","volume":"14","author":"Nakamura","year":"2024","journal-title":"Front Oncol"},{"key":"R20-20260729","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ygyno.2015.02.009","article-title":"Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: a phase 2 study.","volume":"137","author":"Tempfer","year":"2015","journal-title":"Gynecol Oncol"},{"key":"R21-20260729","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ygyno.2018.05.001","article-title":"A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis.","volume":"150","author":"Tempfer","year":"2018","journal-title":"Gynecol Oncol"},{"key":"R22-20260729","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1245\/s10434-023-14648-0","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) applied to platinum-resistant recurrence of ovarian tumor: a single-institution experience (ID: PARROT trial).","volume":"31","author":"Vizzielli","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"R23-20260729","doi-asserted-by":"crossref","first-page":"20180111","DOI":"10.1515\/pp-2018-0111","article-title":"Pressurized intraperitoneal aerosol chemotherapy vs. intravenous chemotherapy for unresectable peritoneal metastases secondary to platinum resistant ovarian cancer - study protocol for a randomized control trial.","volume":"4","author":"Somashekhar","year":"2019","journal-title":"Pleura Peritoneum"},{"key":"R24-20260729","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1515\/pp-2016-0011","article-title":"Peritoneal sampling and histological assessment of therapeutic response in peritoneal metastasis: proposal of the peritoneal regression grading score (PRGS).","volume":"1","author":"Solass","year":"2016","journal-title":"Pleura Peritoneum"},{"key":"R25-20260729","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1016\/j.ejso.2020.05.007","article-title":"Standardizing training for pressurized intraperitoneal aerosol chemotherapy.","volume":"46","author":"Alyami","year":"2020","journal-title":"Eur J Surg Oncol"},{"key":"R26-20260729","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejso.2019.06.028","article-title":"Unresectable peritoneal metastasis treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC) leading to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.","volume":"47","author":"Alyami","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"R27-20260729","doi-asserted-by":"crossref","first-page":"6869","DOI":"10.21873\/anticanres.13062","article-title":"No renal toxicity after repeated treatment with pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with unresectable peritoneal metastasis.","volume":"38","author":"Larbre","year":"2018","journal-title":"Anticancer Res"},{"key":"R28-20260729","doi-asserted-by":"crossref","first-page":"107250","DOI":"10.1016\/j.ejso.2023.107250","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in patients with ovarian cancer: a systematic review.","volume":"49","author":"Taliento","year":"2023","journal-title":"Eur J Surg Oncol"},{"key":"R29-20260729","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.3390\/pharmaceutics13122043","article-title":"The feasibility of pressurised intraperitoneal aerosolised virotherapy (PIPAV) to administer oncolytic adenoviruses.","volume":"13","author":"Tate","year":"2021","journal-title":"Pharmaceutics"},{"key":"R30-20260729","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.addr.2020.10.015","article-title":"Intraperitoneal aerosolized drug delivery: technology, recent developments, and future outlook.","volume":"160","author":"Rahimi-Gorji","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"R31-20260729","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ejso.2021.10.028","article-title":"Consensus guidelines for pressurized intraperitoneal aerosol chemotherapy: technical aspects and treatment protocols.","volume":"48","author":"H\u00fcbner","year":"2022","journal-title":"Eur J Surg Oncol"},{"key":"R32-20260729","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1016\/S1470-2045(19)30318-3","article-title":"Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications.","volume":"20","author":"Alyami","year":"2019","journal-title":"Lancet Oncol"},{"key":"R33-20260729","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.ejso.2017.09.010","article-title":"Multicentric initial experience with the use of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable peritoneal carcinomatosis.","volume":"43","author":"Alyami","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"R34-20260729","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ejso.2017.03.019","article-title":"Pressurized intraperitoneal aerosol chemotherapy - practical aspects.","volume":"43","author":"H\u00fcbner","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"R35-20260729","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1245\/s10434-012-2840-2","article-title":"Renal and hepatic toxicities after pressurized intraperitoneal aerosol chemotherapy (PIPAC).","volume":"20","author":"Blanco","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"R36-20260729","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/bjs.10521","article-title":"Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis.","volume":"104","author":"Grass","year":"2017","journal-title":"Br J Surg"},{"key":"R37-20260729","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1515\/pp-2023-0014","article-title":"Peritoneal regression grading score (PRGS): first evidence for independent predictive and prognostic significance.","volume":"8","author":"Baake","year":"2023","journal-title":"Pleura Peritoneum"},{"key":"R38-20260729","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1186\/s12885-018-4363-0","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for the treatment of malignant mesothelioma.","volume":"18","author":"Giger-Pabst","year":"2018","journal-title":"BMC Cancer"},{"key":"R39-20260729","doi-asserted-by":"crossref","first-page":"6358","DOI":"10.1007\/s00464-021-08567-y","article-title":"Technology development of hyperthermic pressurized intraperitoneal aerosol chemotherapy (hPIPAC).","volume":"35","author":"Bachmann","year":"2021","journal-title":"Surg Endosc"},{"key":"R40-20260729","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.ejso.2015.06.001","article-title":"Quality of life of patients with end-stage peritoneal metastasis treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC).","volume":"41","author":"Odendahl","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"R41-20260729","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s00404-024-07586-z","article-title":"Efficacy and safety of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in ovarian cancer: a systematic review of current evidence.","volume":"310","author":"Pavone","year":"2024","journal-title":"Arch Gynecol Obstet"},{"key":"R42-20260729","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejso.2020.08.020","article-title":"Current practice of pressurized intraperitoneal aerosol chemotherapy (PIPAC): still standardized or on the verge of diversification?","volume":"47","author":"Sgarbura","year":"2021","journal-title":"Eur J Surg Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000045927","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:03:03Z","timestamp":1785351783000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000045927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":41,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000045927","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"2025-06-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}